aqemia.com — August 2026 traffic, keywords & AI visibility

Search engines send aqemia.com an estimated 52 visits a month. Effectively all of it is organic — about 52 visits from unpaid results. Spread across 4 ranking keywords, that averages roughly 13 organic visits per keyword.

aqemia.com scores 59 out of 100 on our AI visibility scale, grade D. It takes full marks for LLMS.txt. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10), Company profile (19/25) and Structured data (0/5).

The llms.txt on aqemia.com runs to 78 lines (5,117 characters) across 12 sections, last generated in May 2026. It introduces the site as "Aqemia - Physics-driven AI for Drug Discovery". It tells AI engines the business works in Drug Discovery, Computational Chemistry and AI for Life Sciences. It describes 4 products, including Aqemia Discovery Platform, Aqemia Oncology Suite and Aqemia Inflammation Module. Services it lists include Collaborative Drug Discovery, Custom Model Development, Screening-as-a-Service and Consulting & Training. It targets Global. Technologies it mentions include Python, TensorFlow, PyTorch, Quantum chemistry packages and High-performance computing clusters. The keywords it claims start with "drug discovery", "AI", "physics-based modeling" and "computational chemistry".

# Aqemia - Physics-driven AI for Drug Discovery

## About
Aqemia is a Paris-based biotech company that blends quantum-inspired physics with machine learning to speed up small-molecule drug discovery. The team works with pharmaceutical partners to identify promising compounds faster and at lower cost than traditional lab-heavy approaches. Their platform models molecular interactions at a level of detail that helps researchers prioritize candidates with better chances of success in the clinic. Founded by scientists who wanted to move beyond brute-force screening, Aqemia focuses on targets that have historically been difficult to drug. The company serves both large pharma groups looking to de-risk early pipelines and smaller biotechs that need efficient hit-finding without massive wet-lab spend. By combining high-accuracy physics simulations with scalable AI, Aqemia claims it can cut the typical early discovery timeline by several months. The platform is already being applied to oncology, inflammation, and rare-disease programs. Leadership has deep roots in computational chemistry and previously worked at institutions such as CEA and Sanofi. The firm raised seed and Series A rounds from European deep-tech investors and maintains a lean team of around sixty people. Aqemia’s headquarters sit in the heart of Paris’s biotech cluster, giving it easy access to academic labs and clinical

Google lists aqemia.com for about 4 keywords, which together bring an estimated 52 organic visits a month.

The latest technical audit of aqemia.com scored 0 out of 100 overall. The audit makes 8 recommendations in all.

Aqemia's company profile names Insilico Medicine, Atomwise, BenevolentAI and Recursion Pharmaceuticals as competitors. Its own llms.txt adds insilico.com, benevolent.com, recursionpharma.com, schrodinger.com and curemetrix.com. Outside its market, the domains ranked closest to it in our worldwide ranking are nicols.com, pzhan.asia, goelles.at and thethompsongroup.net.

Insilico Medicine

Atomwise

BenevolentAI

Recursion Pharmaceuticals

insilico.com

benevolent.com

recursionpharma.com

schrodinger.com